Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Can FDA Do The "Right Thing" On Transparency? Ask A Lawyer

This article was originally published in The Pink Sheet Daily

Executive Summary

Proposals from agency task force include releasing when applications are submitted and withdrawn along with FDA reasons for refuse-to-file and complete response letters.

You may also be interested in...



Biosimilar Labeling Needs Greater Transparency, BIO And PhRMA Say

Need for informed prescribing demands that products include the data that support biosimilarity, trade groups say in joint petition.

FDA’s Guidance Document To-Do List Grows

Since releasing its annual guidance agenda in December, FDA has added a number of guidances to its development agenda.

FDA Transparency Initiative: GSK's Tailored Comments Seek To Shape Plan

FDA's transparency initiative has drawn sharp criticism from drug industry organizations fearful that trade secrets will be divulged, but GlaxoSmithKline is taking a different tack in suggesting modifications rather than condemning them outright

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS070646

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel